Press brief by Francesca Ferrua, MD, at the American Society of Hematology (ASH) 2015 annual meeting. Dr Ferrua provides an update on the safety and eficacy results of a phase I/II clinical trial with hematopoietic stem cell (HSC) gene therapy (GT) for Wiskott-Aldrich Syndrome (WAS). In summary, 7 WAS patients showed that GT is well tolerated and lead to a sustained clinical benefit. The high level of gene transfer obtained with LV-WAS resulted in robust engraftment of transduced HSC, even when combined with reduced intensity conditioning.
Safety and Clinical Benefit of HSC Gene Therapy for Wiskott-Aldrich Syndrome
13th January 2016
Hematology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?